The short answer on durability

For appropriately selected patients, ChondroFiller — placed as an injectable collagen scaffold under ultrasound guidance — maintains both structural integrity and meaningful functional benefit across the 3–5-year window that published clinical data currently cover.

The headline figures are consistent across independent datasets: roughly 70–85% of well-selected patients retain clinically significant symptom relief at that horizon, and more than 81% of those tracked over 12–60 months report good-to-excellent outcomes. The Jerosch prospective post-market clinical follow-up study — the most frequently cited durability dataset — recorded a 32.4-point IKDC improvement that was sustained, and marginally increased, at the 3-year mark, with patients reaching a mean functional score of 80. A 2016 randomised controlled pilot and a series of independent cohort reports reach broadly similar conclusions, and the evidence is synthesised in the manufacturer's April 2025 Clinical Evaluation Report.

One constraint matters throughout: these figures apply to focal, contained cartilage defects in otherwise healthy joints. Durability data do not translate to diffuse joint degeneration or end-stage osteoarthritis, where the biological conditions for scaffold-supported repair are not present. Patient selection is, in that sense, part of the outcome.

What MOCART scores show from four weeks to three years

The four-week MOCART score — a mean of 65.3 across European ChondroFiller knee studies — needs a brief mechanical explanation before it can be read correctly. At that early stage, the injectable collagen scaffold has gelled in the defect but host progenitor cells have barely begun colonising it. MRI at this point is largely capturing the scaffold's water content rather than mature repair tissue, so a score in the mid-60s is mechanistically expected, not a sign that repair has stalled or is insufficient.

As host cells migrate into the matrix — a process confirmed by a 2025 ex vivo model recording a 2.4-fold increase in scaffold DNA content within 14 days of implantation — the tissue matures progressively. By twelve months, MOCART scores across European cohorts have risen to the 81.6–84.3 band, corresponding to greater than 80% defect filling with solid border integration and smooth surface contours. Independent published series place the one-year range between 70 and 87, consistent with the same trajectory.

The clinically meaningful finding is what happens after that: three-year MRI data aligns with the one-year band rather than declining. No progressive structural deterioration has been observed in the available follow-up data. This plateau — not a continuing rise, but a sustained level — is the key durability signal. It reflects a scaffold that has largely completed resorption and been replaced by repair tissue generated through acellular matrix-induced chondrogenesis, where the collagen matrix supports the body's own endogenous repair processes. The rise from four weeks to twelve months should therefore be read as evidence of an orderly biological sequence, not as instability during that interval.

Why results continue to improve into the second year

The collagen scaffold's gradual disappearance is not a limitation of the treatment — it is the mechanism. Over approximately 6–24 months, the matrix progressively resorbs while acting as a biological template, making space for the repair tissue that host cells have been laying down since the first fortnight after injection. Full replacement of the scaffold by maturing repair tissue takes up to two years, which explains a clinical pattern that might otherwise seem counterintuitive: functional and structural scores are marginally higher at 36 months than at 12 months, rather than plateauing once the scaffold has gone.

This trajectory stands in contrast to permanent, space-occupying hydrogels, in which the injected material remains unchanged in the joint over time. Unlike a permanent filler approach, the collagen scaffold is designed to be replaced — the scaffold is transient; the repair tissue it has supported through acellular matrix-induced chondrogenesis is the intended endpoint. What persists beyond 24 months is not the device itself but the cartilage-like layer generated by the patient's own recruited progenitor cells. The repair mechanism supports the body's own endogenous processes rather than substituting a synthetic material for missing tissue.

The Jerosch prospective post-market clinical follow-up study provides the clearest clinical confirmation of this pattern. It recorded a 32.4-point IKDC improvement that was sustained — and marginally increased — at 36 months, with patients reaching a mean functional score of 80 at that point. Framed against the biology, those figures are consistent with continuing tissue maturation through the second and third year rather than an early peak followed by slow regression. The resorption window is not a vulnerability in ChondroFiller's durability profile; in biological terms, it is the reason for it.

Functional outcomes: what patients actually feel at three years

Patients tracked over three years consistently describe a shift from restricted, painful movement to near-normal recreational activity — a change quantified across four independent knee studies as a roughly 30-point rise in IKDC score, from a baseline of approximately 48 to approximately 80. That is not a marginal improvement: the established minimum clinically important difference (MCID) for IKDC is 16.7 points, and these patients have moved close to twice that threshold. The Jerosch PMCF dataset — whose biological underpinning was covered above — puts the specific figure at 32.4 points, sustained at 36 months, consistent with the wider cross-study picture.

Durability extends beyond the knee as well. In a hip cohort of 26 patients treated for acetabular defects and followed for 12–60 months, 17 of the 21 evaluable patients reported good or excellent results — cross-joint confirmation that the 3–5-year durability window is not a feature of knee anatomy alone.

MRI data and functional data converge at a meaningful point, which is worth making explicit: one-year MOCART scores in ChondroFiller studies (81.6–84.3) exceed the MOCART 2.0 threshold of 60 identified in a 2025 ROC analysis as predictive of favourable patient-reported outcomes. That said, a separate 2025 study of 111 patients found no significant overall correlation between MOCART scores and changes in patient-reported outcomes — a finding that reinforces rather than undermines confidence in how to read the numbers. Structural imaging is a supporting indicator; how the patient feels at three years is the measure that ultimately matters. On that measure, the evidence is consistently positive.

Which patients are most likely to see lasting benefit

Durability figures like 70–85% lasting relief at 3–5 years carry an important qualifier: they describe outcomes in carefully selected patients with focal, contained cartilage defects in joints that are otherwise structurally sound. They do not apply to diffuse joint degeneration or end-stage osteoarthritis, where the biological conditions for acellular matrix-induced chondrogenesis — a healthy progenitor cell population, intact subchondral bone, and a mechanically stable joint environment — are substantially compromised.

For patients who do meet those criteria, published reoperation data add a practical dimension to the durability picture. ChondroFiller carries an estimated reoperation rate of approximately 3–8%, compared with rates of up to 41% reported for microfracture and up to 37% for autologous chondrocyte implantation (ACI/MACI). The single-stage, acellular design avoids both the biological ceiling problems associated with microfracture and the two-stage donor-site commitment required by ACI — without compromising the structural and functional outcomes the evidence reflects.

Patients presenting with wider-spread joint degeneration are unlikely to replicate these results and should anticipate a different treatment conversation, one that may centre on symptom management rather than tissue restoration.

Determining which category a given patient falls into requires formal cartilage defect classification by a specialist with specific experience in joint-preservation assessment. That evaluation — not the durability data in isolation — is the necessary starting point for any realistic treatment decision.

What the evidence does not yet cover

Three specific limitations are worth naming plainly, rather than distributed as hedges across the sections above.

The study designs are prospective case series, smaller comparative reports, and registry data — there is currently no large, independent, multi-centre RCT specific to ChondroFiller. That matters for precise effect-size certainty, even though the direction and magnitude of findings have been consistent across independent cohorts and across joints.

The five-year horizon is where the published evidence currently stops. Beyond that window, the durability question is genuinely open — not because any signal of late failure exists, but because the data simply do not yet reach further. Longer-term registry follow-up would be the most useful next addition to the evidence base.

Neither limitation warrants dismissing the existing data. Consistency across independent cohorts, an observed biological mechanism, and cross-joint replication are not trivial properties. They mean the current evidence is meaningful within its scope.

For any individual patient, the relevant question is not whether the five-year durability record is adequate in principle — it is whether their specific defect, joint condition, and long-term activity demands make them a candidate for whom that record applies. A specialist cartilage consultation at londoncartilage.com is the appropriate place to answer that.

1. [1] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Correlation and Comparative Evaluation of MOCART and MOCART 2.0 for Assessing Cartilage Repair. (2025). https://doi.org/10.3390/medicina61040745 https://doi.org/10.3390/medicina61040745
3. [3] MOCART 2.0 score of 60 or greater at 1 year post-op predicts favourable clinical outcomes after surgical repair of tibiofemoral cartilage lesions. (2025). https://doi.org/10.1002/ksa.70086 https://doi.org/10.1002/ksa.70086
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y